Hims & Hers Health Investigated for Deceptive Practices Following Stock Drop
Investors who incurred substantial losses in Hims & Hers Health stock are urged to come forward as lead plaintiffs in a securities class action lawsuit concerning alleged deceptive privacy and billing practices.
Hims & Hers Health, Inc. is facing a securities class action lawsuit following a significant stock decline after the Federal Trade Commission (FTC) filed a complaint against the telehealth provider. The company's stock fell 14.73%, or $4.32, to close at $25.00 on July 29, 2026, amidst heavy trading volume.
The FTC alleges that Hims & Hers Health shared sensitive consumer health information with third-party advertising platforms, contradicting its stated privacy policies. Additionally, the complaint asserts that the company deceived users about its billing practices, including charging for prescriptions almost immediately after users submitted intake forms.
Law firm Kahn Swick & Foti, LLC, is reminding investors who purchased Hims & Hers Health securities between August 4, 2025, and July 29, 2026, and suffered significant losses, that the deadline to file lead plaintiff applications is November 2, 2026. The lawsuit is pending in the United States District Court for the Northern District of California.
The case, Velanki v. Hims & Hers Health, Inc. et al., alleges violations of federal securities laws. Interested investors are encouraged to contact Kahn Swick & Foti to discuss their legal rights and potential recovery.